《特应性皮炎外用治疗与管理专家共识（2025版）》发布

Core Viewpoint - The publication of the "Expert Consensus on the Treatment and Management of Atopic Dermatitis (2025 Edition)" provides standardized clinical application guidance for the innovative drug, Zhilimab Benmodem Cream, specifically for atopic dermatitis treatment in China [1] Group 1: Disease Prevalence and Treatment Options - The prevalence of atopic dermatitis among children in China is reported to be between 10% and 15% [1] - For mild to moderate cases, which account for two-thirds of patients, Zhilimab Benmodem Cream is recommended as an important treatment option based on research data from the Chinese population [1] Group 2: Mechanism and Approval - The aryl hydrocarbon receptor (AhR) is identified as a key mediator in the interaction between environmental factors and immune system components, playing a role in maintaining skin homeostasis and alleviating skin inflammation [1] - Zhilimab Benmodem Cream, developed by Shanghai Zedeman Pharmaceutical Technology Co., Ltd., is approved for the treatment of mild to moderate atopic dermatitis in children aged 2 years and older, with its market launch scheduled for November 2024 [1] Group 3: Consensus Development - The consensus was led by Professor Zhang Jianzhong from Peking University People's Hospital, involving 32 experts from dermatology, allergy, and pediatrics, and was established after four rounds of validation [1] - The consensus references 65 domestic and international research studies to create a standardized topical medication treatment system tailored to Chinese patients [1]